Immobilization of Babirusa (Babyrousa babyrussa) with Xylazine and Tiletamine/Zolazepam and Reversal with Yohimbine and Flumazenil

Twelve babirusa (Babyrousa babyrussa) (four females/eight males) were immobilized 30 times during a 4-yr interval. Significantly higher premedication and immobilizing doses were needed for females than for males (P &lt 0.05). An i.m. preanesthetic xylazine dose of 1.88 ± 0.37 mg/kg (range = 1.20...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of zoo and wildlife medicine 1999-12, Vol.30 (4), p.521-525
Hauptverfasser: James, Stephanie B., Cook, Robert A., Raphael, Bonnie L., Stetter, Mark D., Kalk, Penny, MacLaughlin, Kathy, Calle, Paul P.
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Twelve babirusa (Babyrousa babyrussa) (four females/eight males) were immobilized 30 times during a 4-yr interval. Significantly higher premedication and immobilizing doses were needed for females than for males (P &lt 0.05). An i.m. preanesthetic xylazine dose of 1.88 ± 0.37 mg/kg (range = 1.20-2.12 mg/kg) was used for females and 1.22 ± 0.16 mg/kg (range = 0.82-1.43 mg/kg) for males. After xylazine, the animals were induced with i.m. tiletamine/zolazepam; females received 2.20 ± 0.47 mg/kg (range = 1.78-3.33 mg/kg) and males received 1.71 ± 0.34 mg/kg (range = 1.08-2.05 mg/kg). Anesthesia was reversed with yohimbine (0.14 ± 0.03 mg/kg; range = 0.07-0.20 mg/kg) and flumazenil (1 mg flumazenil/20 mg zolazepam) either i.m. or i.v. This anesthetic combination produced smooth induction, good relaxation, and sufficient immobilization to perform routine diagnostic and therapeutic procedures (venipuncture, hoof and tusk trims, transportation, radiographs, ultrasound examination, weight determinations, and skin biopsies). Supplemental ketamine HCl or isoflurane was administered to two animals to effectively deepen or prolong the anesthetic plane, with no resultant adverse effects.
ISSN:1042-7260
1937-2825